Antisense oligonucleotide-mediated terminal intron retention of endoglin: A potential strategy to inhibit renal interstitial fibrosis
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · 2024
DOI: 10.1016/j.bbadis.2024.167186 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2024. Verfasst von Tessa Gerrits und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Leiden University Medical Centre, 2333 ZA Leiden, Netherlands. Electronic address: t.gerrits@lumc.nl. Hauptthemen laut MEDLINE: Fibrosis, Endoglin, Oligonucleotides, Antisense, Introns. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
TGF-β is considered an important cytokine in the development of interstitial fibrosis in chronic kidney disease. The TGF-β co-receptor endoglin (ENG) tends to be upregulated in kidney fibrosis. ENG has two membrane bound isoforms generated via alternative splicing. Long-ENG was shown to enhance the extent of renal fibrosis in an unilateral ureteral obstruction mouse model, while short-ENG inhibited renal fibrosis. Here we aimed to achieve terminal intron retention of endoglin using antisense-oligo nucleotides (ASOs), thereby shifting the ratio towards short-ENG to inhibit the TGF-β1-mediated pro-fibrotic response. We isolated mRNA from kidney biopsies of patients with chronic allograft disease (CAD) (n = 12) and measured total ENG and short-ENG mRNA levels. ENG mRNA was upregulated 2.3 fold (p < 0.05) in kidneys of CAD patients compared to controls, while the percentage short-ENG of the total ENG mRNA was significantly lower (1.8 fold; p < 0.05). Transfection of ASOs that target splicing regulatory sites of ENG into TK173 fibroblasts led to higher levels of short-ENG (2 fold; p < 0.05). In addition, we stimulated these cells with TGF-β1 and measured a decrease in upregulation of ACTA2, COL1A1 and FN1 mRNA levels, and protein expression of αSMA, collagen type I, and fibronectin. These results show a potential for ENG ASOs as a therapy to reduce interstitial fibrosis in CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Leiden University Medical Centre, 2333 ZA Leiden, Netherlands. Electronic address: t.gerrits@lumc.nl.
- Department of Pathology, Leiden University Medical Centre, 2333 ZA Leiden, Netherlands.
- Department of Nephrology, Leiden University Medical Centre, 2333 ZA Leiden, Netherlands.
Zitieren
APA
Gerrits, T., Dijkstra, K. L., Bruijn, J. A., Scharpfenecker, M., Bijkerk, R., & Baelde, H. J. (2024). Antisense oligonucleotide-mediated terminal intron retention of endoglin: A potential strategy to inhibit renal interstitial fibrosis. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. https://doi.org/10.1016/j.bbadis.2024.167186
Vancouver
Gerrits T, Dijkstra KL, Bruijn JA, Scharpfenecker M, Bijkerk R, Baelde HJ. Antisense oligonucleotide-mediated terminal intron retention of endoglin: A potential strategy to inhibit renal interstitial fibrosis. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2024. doi:10.1016/j.bbadis.2024.167186
BibTeX
@article{Gerrits2024,
author = {Gerrits, Tessa and Dijkstra, Kyra L and Bruijn, Jan Anthonie and Scharpfenecker, Marion and Bijkerk, Roel and Baelde, Hans J},
title = {Antisense oligonucleotide-mediated terminal intron retention of endoglin: A potential strategy to inhibit renal interstitial fibrosis},
journal = {Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease},
year = {2024},
doi = {10.1016/j.bbadis.2024.167186}
}
EUVIMED